Screening for depression in cArDiovascular patients at a tertiary Centre in TrinidAd and Tobago: The SAD CAT study

CURRENT STATUS: UNDER REVIEW

Naveen Seecheran
The University of the West Indies at Saint Augustine

nseecheran@gmail.com Corresponding Author
ORCiD: https://orcid.org/0000-0002-7779-0181

Cathy-Lee Jagdeo
The University of the West Indies at Saint Augustine

Rajeev Seecheran
The University of the West Indies at Saint Augustine

Valmiki Seecheran
The University of the West Indies at Saint Augustine

Sangeeta Persad
The University of the West Indies at Saint Augustine

Lakshmipatty Peram
The University of the West Indies at Saint Augustine

Mathew Evans
The University of the West Indies at Saint Augustine

Justine Edwards
The University of the West Indies at Saint Augustine

Sheri Thackoorcharan
The University of the West Indies at Saint Augustine

Britney Davis
The University of the West Indies at Saint Augustine

Shari Davis
The University of the West Indies at Saint Augustine
DOI: 10.21203/rs.3.rs-17775/v1

SUBJECT AREAS
Psychiatry

KEYWORDS
screening, depression, cardiovascular disease, Trinidad and Tobago, Patient Health Questionnaire-9 (PHQ-9)
Abstract

Objectives This was an observational, cross-sectional study aimed to screen cardiovascular patients for depression at a tertiary center in Trinidad and Tobago; and to determine any significant associations amongst patients’ demographics, comorbidities, and cardiovascular medications with depressive symptoms.

Methods Patients (n=1203) were randomly selected from the cardiology outpatient clinics at the Eric Williams Medical Sciences Complex. After meeting selection criteria, informed consent was obtained, and patients were administered a case report form, which included the Patient Health Questionnaire-9 (PHQ-9).

Results The study had a 96% respondent rate, whereby the average age was 62 years old. 47.5% were male, and 52.5% were female. 90.2% of the sample had cardiovascular disease. 25% of the sample had a PHQ-9 score of ≥ 10, with 19.3% having no depressive symptoms. Females, lower levels of education and income were found to be statistically significant at risk for depression (all p-values <0.001). Comorbidities associated with depression included hypertension, prior cerebrovascular events, chronic kidney disease and chronic obstructive pulmonary disease with odds ratios (OR) and 95% confidence intervals (CI) of OR 1.988 (CI 1.414-2.797), OR 1.847 (CI 1.251-2.728), OR 1.872 (CI 1.207-2.902) and OR 1.703 (CI 1.009-2.876) respectively. Only the cardiovascular medication of ticagrelor was found to be significantly associated with depression (p-value <0.001).

Conclusion 1 in 4 screened cardiovascular patients displayed significant depressive symptoms with a PHQ-9 ≥ 10. The information acquired from this study may be useful in developing screening protocols that can positively impact adherence and possibly attenuate future events. This study also highlights the importance of implementing a multidisciplinary approach to managing cardiovascular disease and screening for depression. Further studies are required to validate these findings (ClinicalTrials.gov number, NCT03863262).

Introduction

Cardiovascular disease (CVD), as well as depression, are highly prevalent diseases. They both account for a significant decrease in quality of life for the patient and impose a significant socioeconomic
burden. (1) There is mounting evidence that depression can be considered an independent risk factor to incur a cardiovascular (CV) event. (1)

CVD is the leading cause of mortality worldwide, and this is no different in Trinidad and Tobago, where it accounts for up to 40% of adult mortality annually. (2) Trinidad and Tobago's economy is chiefly derived from petrochemical energies and, to a minor extent, agriculture, and tourism. The national population is approximately 1.4 million and multiethnic with nearly equal representation from South Asian, Caribbean Black, and interracial groups. (2) (3)

Depression, defined as a mood disorder that causes a persistent feeling of sadness and anhedonia, has skyrocketed from the fourth leading cause of disability to the leading cause globally over the past two decades, according to the World Health Organization (WHO). (4)

Depression is the most common mental disorder in an ambulatory care setting with almost one-tenth of patients meeting criteria for major depression. While the literature is replete with studies reporting depression in an outpatient setting, the majority of Trinidadian studies have focused on hospitalized patients and suicide. (5) Depression has an estimated prevalence of nearly 15% amongst patients visiting their family physicians, almost 30% among patients with chronic diseases, and approximately 20% among patients treated for type 2 diabetes mellitus. (5) (6)

Depression is highly coincident in patients with CVD. Approximately one-third to almost one-half of these patients suffer from clinically significant depression, with more than one-fifth of patients fulfilling the criteria for major depressive disorder (MDD). (4) Coronary artery disease (CAD) appears to be the most common type of CVD associated with depression. Patients with atrial fibrillation, chronic heart failure, coronary artery bypass grafting surgery, and cardiac implantable electronic devices have also been observed to have an elevated risk for depression and MDD. (4) CV patients also possess an increased tendency for other psychiatric illnesses such as generalized anxiety disorder (GAD) and posttraumatic stress disorder (PTSD). (4)

In a previous study, 40% of hospitalized CV patients displayed clinical depression. (7) Comparatively, in another local study, using the Centre for Epidemiologic Studies (CES) Depression scale, it was found that almost half of patients with self-reported CVD had depressive symptoms and, conversely, a
little more than one-third of patients with depressive symptoms had no self-reported CVD. (8)

The pathophysiology of depression is complex and multifactorial; and involves genetic, psychosocial, and neurohumoral factors. (9) (10) Contrarily, the pathophysiology of CVD is relatively better understood. A common implicated pathophysiological mechanism appears to be inflammation; however, it cannot account for the entirety of a causal link between the two conditions. (11)

Depression is considered to be a risk factor for developing CVD, as it has attendant effects on endothelial dysfunction, atherosclerotic plaque integrity, the hemostasis-thrombosis axis, and cardiac myocyte electrophysiology. (12) The American Heart Association (AHA) now recommends that depression should be recognized as a risk factor for CVD similar to traditional risk factors such as diabetes mellitus (DM), hypertension (HTN), and dyslipidemia (HLD). (13) Notably, there is an increased mortality rate in adults with depression with or without CVD. (13) Depression has been shown to have a deleterious impact on patients with CVD with respect to lifestyle, treatment, and compliance. (13) Furthermore, it is associated with a diminished quality of life and worsens the overall prognosis. (14)

There is a multitude of investigational tools and screening questionnaires used to assess symptoms of depression, such as the Beck's Depression Inventory (BDI), Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-9 (PHQ-9) and the Zung Depression Rating Scale (ZDRS). The PHQ-9 has been shown to have reasonable sensitivity and specificity for patients with CVD and proven useful in limited-resource settings. (15) (16) (17) It is recommended that physicians use tools such as the PHQ-9 to screen patients with CVD for depression as there is a bidirectional link. (16) (18) (19) (20) Other key advantages of the PHQ-9 include that it is a swift, accurately grades severity of depression and can be used to reassess patients on antidepressant therapy. (21) The disadvantages are that it may misdiagnose depression and does not include exclusion criteria for other mood disorders. (21)

The principal aim of this study is to screen cardiovascular patients for depression at a tertiary center in Trinidad and Tobago; and to determine any significant associations amongst patients’ demographics, comorbidities, and cardiovascular medications with depressive symptoms.

Methods And Materials
Study design and patient population

The study design was a cross-sectional, descriptive study performed at the Eric Williams Medical Sciences Complex (EWMSC), Trinidad, during the timeframe of December 2018 to June 2019. EWMSC is considered the major cardiovascular tertiary hospital under the North Central Regional Health Authority (NCRHA). The populous of Trinidad and Tobago is approximately 1.4 million people, in which the north-central distribution of the country seeks healthcare at this institution. (2) The primary objectives of the study were to screen patients for depression in those with CVD in Trinidad and Tobago and to determine any significant associations amongst patients' demographics, comorbidities, and cardiovascular medications with depressive symptoms.

Patient interview and case report form

Patients for the study were recruited from the cardiology outpatient clinics (COPCs) at EWMSC. Patients were screened with a stratified permuted block randomization technique, which applied to recruitment days (weekdays during standard working hours). Randomization sequence numbers were obtained from Statistical Package for Social Sciences (SPSS) version 24.0 software (International Business Machines (IBM) SPSS Statistics, New York, USA). On average, 100 patients were enrolled every week for three months. Patients were recruited in the study while waiting to see their clinic physician in a private, confidential consultation room. Once informed consent was obtained from these patients, a case report form with the PHQ-9 questionnaire was administered to these patients by the primary investigator. The depression screening tool used in the questionnaire of this study was the PHQ-9. Based on the prior studies, a PHQ-9 ≥ 10 has been noted to have a specificity and sensitivity of 88% for major depression and, thus, was used as a cut-off to represent the percentage of patients with significant depressive symptoms. It was selected primarily because it is user-friendly and used in several similar studies. (22) This tool also allowed researchers to assess the category of depression into mild, moderate, and severe. Patients were enrolled in the study once they fulfilled selection criteria. The inclusion criteria for participation in the study included patients who were officially registered at the COPC and ≥ 18 years old. The exclusion criteria for participants included unregistered patients, patients < 18 years old, declined participation, and inpatients requiring
hospitalization. No particular gender groups were excluded from this study, nor were any ethnic or racial groups were excluded.

Sample size calculation

The final number of enrolled participants in this study was 1203 patients. There were no “dropped” participants, nor were there any incomplete questionnaires by any participants. Based on a study done by Huffman, it was estimated that 40% of patients with CVD also have depression and utilizing a type I error rate of 5% ($\alpha = 0.05$), a statistical power of 90%, 10% patient decline and attrition rate with a minimum detectable difference of 10%, the estimated sample size was calculated to be 1203 patients. (4)

Serious adverse events

Data collection was performed by the principal investigator, who is a licensed practicing physician. The principal investigator was also responsible for the management of any serious adverse events (none occurred), such as an acute cardiovascular or psychiatric condition. Any treatment would be administered at the EWMSC emergency department, located approximately 1–2 minutes by an attendant-escorted wheelchair. The potential risks associated with the PHQ-9 were low and included psychological trauma, feelings of depression, and acute psychosis. Participants were monitored during the questionnaire by the principal investigator for the emergence of any of the stated potential risks.

Ethical approval

The principal investigator initially completed a prerequisite ethics course designed by the Collaborative Institutional Training Initiative (CITI) before the application for approval. Full ethical approval was granted by the campus research ethics committee (CREC) of the University of the West Indies, St. Augustine (UWI STA). Additionally, institutional approval was obtained from the Public Health Observatory (PHO). The study has been registered with the clinical trials registration site ClinicalTrials.gov number, NCT03863262.

Confidentiality of patients was ensured as no patient names were recorded, and all existing data recorded was de-identified. Patients were uniquely identified using their medical record numbers of
the COPC. Additionally, the data was only accessible to the primary investigator of the study. The data was stored on a password-protected, encrypted database on a workstation located in a locked office. The scores of the PHQ-9 were verbally communicated to the patients in confidentiality by the primary investigator with the interpretation of the score. Patients were allowed to decide if they wanted the results communicated to their supervising physician in the COPC, and if so, the results were disseminated to their respective physicians who would have then decided on appropriate referrals.

Statistical analysis

SPSS version 24.0 software (IBM SPSS Statistics, NY, USA) was utilized for data analytics for both descriptive and inferential statistical methods. Descriptive methods included frequency and percentage and summary statistics. Inferential methods included 95% confidence intervals (CIs), independent sample t-test, Fisher’s exact test, and Chi-square test. Adjusted odds ratios were used to determine the strength of the associations. Statistical significance was accepted as a p-value < 0.05.

Results

Demographics

Out of 1253 patients approached, 1203 provided informed consent to participate in the study, giving an overall response rate of 96%. The average age of the study population was approximately 62 years old, with the distribution bear equivalent for males and females (Table 1). There were no other gender groups. The female population was found to have more depressive symptoms than the male population with a p-value of <0.001 (Table 4). The majority of patients in the study were of South Asian descent, which comprised almost three-fifths of the participants, whereas Caribbean Blacks comprised approximately one-third (Table 1). Chi-square testing revealed no associations between depression and ethnicity in this population of patients.

Based on the educational background of the study population, one-half of patients had primary school education while a little more than 5% of the population had no education. The income levels of these patients ranged from almost 30% of patients having no income at all, with slightly more than half of
the patients being pensioners while 3.1% o earned more than TTD 10,000.00 per month (Table 1).

Patients with no education and very low-income brackets were found to statistically significant for depressive symptoms using Fisher’s Exact test.

Comorbidities
Approximately 90% of these patients had CVD, where one-tenth of these patients were registered patients of the COPCs who were referred for suspected CVD awaiting advanced investigations such as coronary angiography and stress testing. Nearly half of the patients were diabetic and dyslipidemic, and nearly three-quarters of patients were hypertensive (Table 2). The number of diseases was positively correlated with having major depression with an odds ratio (OR) of 1.248 (95% CI 1.125-1.384). Additionally, the number of drugs was positively correlated with having major depression with an OR of 1.062 (95% CI 1.005-1.123). When adjusted for age, gender, ethnicity, income, and level of education, there were several diseases associated with depression in this study. CVD, HTN, CKD, and COPD were all significantly associated with depression with ORs and 95% CIs of 1.988 (CI 1.414-2.797), 1.847 (CI 1.251-2.728), 1.872 (CI 1.207-2.902) and 1.703 (CI 1.009-2.876) respectively (Table 5).

Cardiovascular Medications
Almost 70% of the study population was on aspirin, while a little less than one-third were on clopidogrel (Table 3). Approximately 2% of patients were on ticagrelor therapy. Nearly one-tenth of patients were on vitamin K antagonists (VKA), and 1% of patients were on direct oral anticoagulants (DOACs). Just over half of the patients were on a statin. Less than one-fifth of patients were on calcium channel blockers (CCB) as compared to almost half of patients that were on beta-blocker therapy (BB) (Table 3). With respect to medication use, the only significant association between depression and medication use was found with ticagrelor with a p-value of 0.001 (Table 6). Out of 304 patients with PHQ ≥ 10, approximately 5% were on ticagrelor. There were no statistically significant associations found between depression and the use of BB, CCB, ACE inhibitors (ACEi), ARBs, and statins.

Discussion
The categories of depression were divided into no depression, minimal depression, mild depression, moderate depression, moderately severe depression, and severe depression based on the PHQ-9 score. Patients with significant depressive symptoms were defined as a patient who had a PHQ-9 score of $\geq 10$. PHQ-9 scores $\geq 10$ would include the categories of moderate depression, moderately severe depression, and severe depression. This cut-off was used as it has a sensitivity and specificity of 88% for detecting MDD and useful in determining the severity of depression (22) It should also be underscored that the PHQ-9 was not used as a diagnostic tool but as a screening modality for depression for which it has a reliable track record. (23) Intrinsically, it possesses high sensitivity and negative predictive value; however, its sensitivity and positive predictive value were low, making it an optimal choice to screen patients for depression but not in establishing a diagnosis. (24) In our setting, it was applicable as the patients were willing to participate as the questionnaire only comprised a relatively small number of questions. This made it easy to understand and not very time consuming, hence such a high respondent rate for the study. Also, the PHQ-9 has been proven to be useful across multi-ethnic groups, which included American Blacks, Hispanics, and Caucasians, making it very useful in our cosmopolitan setting. (25) One disadvantage of the PHQ-9 is that it is not a diagnostic tool, and thus if patients score $\geq 10$, they need further evaluation for the diagnosis of depression. (24)

In this study, it was found that approximately 25% out of 1203 patients had significant symptoms of depression, while only nearly one-fifth of this population had no symptoms of depression. This is an alarming finding and alludes to depression being overlooked as a coincident diagnosis. Of importance, in this study, patients who were found to have a PHQ $\geq 10$ were advised to seek further evaluation from a psychiatrist for a more in-depth evaluation. In the study, no respondents required emergent admission to the emergency department or psychiatric unit. Significantly, no patients were previously diagnosed or provided a medical history of depression, although approximately 25% of this population had significant depressive symptoms. In a population with CVD, the prevalence of depression is three-fold higher than that of the general population and, thus, was likely under-diagnosed, despite being reported as a risk factor. (13) Those who have depression with CVD have a worse outcome than those
who are not depressed. (26) This finding may be supported as patients who are depressed are likely to be non-compliant with therapy for their condition. (26) Thus, it is imperative to screen this population of patients to attenuate CV morbidity and mortality, although few studies have shown that community-based screening for depression improves outcomes. (27)

Demographics

In this study, the mean age of the participants was 62 years old, in which female patients were more likely to have significant depressive symptoms as compared to males. This gender disparity is consistent with a multitude of other studies, generally indicating a 1.7-fold higher incidence and prevalence in women. (28) (29) Some postulated causes for this trend include hormonal effects, amongst other issues, such as cultural differences. (28) In this study, 64.5% of females displayed depressive symptoms determined by a PHQ-9 ≥ 10. Both genders were nearly equally represented, with women being more marginally included. Generally, women tend to have internal features of depression, whereas men display external features of depression. (28)

There were no significant associations between any particular ethnic group and depression found in this study. In comparison, in another study that compared Caucasians, Hispanics, and American Blacks, it was found that depression was more prevalent among the minority groups. (30) Possible explanations for these findings were that the minority groups were more likely to be female, lived alone, had one living parent, and more chronic diseases. (30) (31)

Physical health was another variable that impacted the rates of depression amongst different ethnic groups as it was found in England that South Asians were more depressed than Caucasians as a result of lesser physical health status (32). In another local study assessing hospitalized patients with cardiac disease for depression, no particular ethnic group was significantly more depressed as similarly illustrated in this study. (7) Of note, there is a paucity of local data comparing Caribbean ethnicities and their association with the prevalence of depression. About half the population had only a primary level of education. In contrast, a little more than one-tenth of the population had no formal education, and this subgroup was found to have statistically significant depressive symptoms as compared to other educational levels. It is well recognized that lower levels of education are
associated with a higher rate of depression in westernized societies and likely attributed to socioeconomic factors. (33) In China, it was found that lower levels of education were also associated with lower socioeconomic status and, consequently, an increased likelihood for the development of MDD in a female population cohort. (34) Conversely, the Trøndelag Health Study (HUNT) study revealed a cumulative protective effect of higher levels of education for depression and anxiety. (35) Some proposed hypotheses that confer this protective effect include higher education level, satisfactory occupations with higher levels of income, healthier lifestyle practices, and enhanced coping mechanisms with stressors. (36) Therefore, it can be seen that the relationship between low education levels and depression has been firmly established worldwide.

Patients with no income or pensioners were found to have significant depressive symptoms (PHQ-9 ≥ 10). In a major systematic review, depression was more prevalent in populations where there is a higher degree of income inequality. (37) Additionally, the European Social Survey 2006/2007 found that income inequality was associated with higher rates of depression. (38) It was similarly found that almost one-third of people with depression were in the lowest income or wealth categories as compared to one-tenth in the higher income brackets. (39) These findings were also replicated in this study. Family or household income seems to have some protective effect against depression, as proposed in another study. (40) Hypothesized theories include two main theories of social causation and social selection. (41) Depression may cause stress, reduced coping mechanisms, and adversity, which may be the etiology of low-income settings and increased risk for the development of mental illness as per the social causation theory. (41) The social selection hypothesis postulates that those with mental illness are more likely to have a reduction in socioeconomic status as a result of possible genetic factors, increased incidence of hospitalizations, and increased rates of unemployment. (41) Comorbidities

90% of 1203 respondents were reported as having CVD in the sample population. However, the remaining 10% of patients were still registered patients of the COPC at EWMSC with no confirmed cardiac diagnosis at this point of evaluation. This is likely attributed to patients being referred from primary care physicians or other specialty clinics for suspected cardiac disease and require either
consultations or further workup with investigations such as coronary angiography and stress testing. They were still included in the sample as an all-comers study as they were formally registered patients. Depressive symptoms were prevalent in other disease conditions in this study. These included HTN, CVEs, CKD, and COPD after being adjusted for age, gender, income, and education levels. It was found that both diseases, depression, and HTN can impact on each other. (42) Hence, patients who were depressed were found to have poorly controlled HTN, while patients with HTN were found to have depression. (42) The prevalence of depression in patients with HTN was found to be 26.8%. (43) Unexpectedly, there was no association found between patients with DM and significant depressive symptoms even though some literature has supported this association. In another local study done in 2013, it was found that depression was significant among patients with DM. (44) This association linking depression and DM was also found when studied in patients from Malaysia, where patients were found to be depressed likely as a result of diabetic complications. (45) In the Madrid Diabetes Study, patients with DM were also found to have depression most likely as a result of their diabetic complications. (46) A plausible rationale for this association of depression and DM may be linked to the use of insulin therapy as it was found that patients on insulin therapy had a higher risk of depressive symptoms. (47) The importance of these associations between depression are other comorbidities lies in the fact that poorly controlled depression, poorly controlled DM, and other poorly controlled diseases are linked to worse outcomes and result in an overall health economic cost. (48) Likewise, there is a relationship between patients who suffered a CVE and depression. Depression was found to be 1.77-times more common in those patients with a previous CVE after suffering an index event. (49) Patients with CKD have also been found to have varying levels of depression. (50) There have been studies which reported that patients with CKD who have depression are undertreated. (51) Similarly, depression is common in patients with COPD. The prevalence of depression in COPD is approximately 40%. (52) The relationship between COPD and depression also seems to be bidirectional. (53)

Cardiovascular Medications

Only ticagrelor had a statistically significant relationship with depressive symptoms. It is important to
note that a pertinent finding from the study was that patients on BB therapy did not exhibit any significant depressive symptoms despite it being stigmatized as a common culprit. Some studies refute this BB-induced depression. (54) Similarly, CCBs are common drugs implicated in drug-induced depression. Interestingly, there is some degree of controversy with respect to if CCB therapy is linked to depression and increased suicidal rates. In a Swedish observational study, there was a significant correlation between the use of CCB and suicide after being adjusted for age and sex. (55) In this study, that correlation was not found between the use of CCB and depression. Another class of drug used in the treatment of CVD includes statins. In this study, there was no correlation between statin therapy and depression. However, in a Swedish cohort, it was found that statins, specifically simvastatin, may have some protective effect against depression, especially in patients over the age of 40 years old. (56)

The drug ticagrelor is an antiplatelet, a direct-acting inhibitor of adenosine diphosphate (ADP) receptor P2Y12. (57) In the PLATO trial, out of 9235 patients, approximately 1.1% of patients experienced depression with ticagrelor. (57) When compared to clopidogrel, another antiplatelet agent, the rate of depression was quite similar. (57) 15 of 27 of patients taking ticagrelor had a PHQ-9 ≥ 10. This finding may have been related to depression being associated with the CVD for which ticagrelor was initiated. Reports in the WHO database from New Zealand and various other countries may suggest a possible safety concern regarding ticagrelor and depression and suicidality. The safety concern has been investigated, and no link between ticagrelor and depression and no depression nor suicidality was demonstrated. (58)

Strengths of the study

One of the significant strengths of the study was that it was adequately powered and met the pre-specified sample size of 1203 participants. To date, this is the most extensive study with respect to sample size, to screen for depression in CVD patients in Trinidad and Tobago. There is also a high study participant response rate, which is typical in a hospital setting. A vital feature of the study was that it was conducted at the EWMSC, which is considered an academic tertiary medical center that specializes in CV care. As a result, it is the only public institution that routinely performs coronary
angiography and cardiac electronic implantable devices. This would improve overall external validity, generalizability, and applicability of the study findings as it encompasses a diverse patient catchment. Additionally, multiple analyses were performed, which were adjusted for age, gender, ethnicity, income, and level of education to mitigate any confounding and interaction effects. An interesting trend or signal was that the unadjusted analyses were similar to the adjusted, suggesting minimal interference from external factors.

Limitations of the study

The study is of a cross-sectional design and thus only reflects the population's depressive symptoms within a specific timeframe. There are also inherent flaws associated with an administered questionnaire, such as verifying the extent of truthful responses, alluding to a Hawthorne effect in which individuals modify an aspect of their behavior in response to their awareness of being observed. (59) Finally, the PHQ-9 has not been previously validated in Trinidad as has the BDI.

Conclusion

1 in 4 screened CVD patients displayed significant depression symptoms, which are likely to translate into a higher rate of CV events. The information gleaned from this study can inform national policy to improve screening measures and possibly attenuate future CV events. It also underscores the imperative need for implementing a multidisciplinary approach to managing CVD. Further comparable studies with national reference data are required to validate these findings.

Abbreviations

| Term                   | Abbreviation               |
|------------------------|----------------------------|
| cardiovascular disease | CVD                        |
| cardiovascular         | CV                         |
| MDD                    | Major depressive disorder  |
| CIED                   | Cardiac implantable electronic device |
| GAD                    | Generalized anxiety disorder |
| PTSD                   | Post-traumatic stress disorder |
| CES  | Centre for Epidemiologic Studies |
|------|----------------------------------|
| AHA  | American Heart Association       |
| AD   | Antidepressant                    |
| CAD  | Coronary artery disease           |
| ACS  | Acute Coronary Syndromes          |
| CVE  | Cerebrovascular event             |
| T2DM | Type 2 diabetes mellitus          |
| BDI  | Beck Depression Inventory         |
| PHQ  | Patient Health Questionnaire      |
| ZDRS | Zung Depression Rating Scale      |
| EWMSC| Eric Williams Medical Sciences Complex |
| NCRHA| North Central Regional Health Authority |
| COPC | Cardiology outpatient clinic      |
| SPSS | Statistical Package for Social Sciences |
| IBM  | International Business Machines  |
| NY   | New York                          |
| USA  | United States of America          |
| CREC | Campus Research Ethics Committee  |
| CITI | Collaborative Institute Training Initiative |
| IRB  | Institutional Review Board        |
Declarations
Funding
Not applicable.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author on request.
Author contributions

All authors conceptualized, designed, conducted, and reviewed the study, and wrote and revised the manuscript. All authors read and approved the final manuscript.

Corresponding Author’s information

NS is an Interventional Cardiology Consultant and Lecturer in Medicine at the University of the West Indies, St. Augustine, Trinidad and Tobago.

Ethics approval and consent to participate

Full ethical approval was granted by the campus research ethics committee (CREC) of the University of the West Indies, St. Augustine (UWI STA). Additionally, institutional approval was obtained from the Public Health Observatory (PHO). All participants gave verbal and expressed written consent to participate in the study.

Consent for publication

Not applicable.

Conflict of Interest, Competing Interests, Financial Disclosure:

The author declares she has no competing interests, and there are no financial disclosures.

Compliance with Ethical Standards:

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

1. Zellweger MJ, Osterwalder RH, Langewitz W, Pfisterer ME. Coronary artery disease and depression.
Eur Heart J [Internet]. 2004 Jan 1 [cited 2019 Jan 5];25(1):3–9. Available from: https://academic.oup.com/eurheartj/article/25/1/3/619401

2. Seecheran N, Baldeo S, Balbosa K, Baksh S, Bethelmy S, Balkaran S, et al. Epidemiologic insight into Trinidad’s awareness and prevention of heart disease. The EPITAPH study - a trinidadian cardiovascular health literacy survey [Internet]. Vol. 4, International Journal Of Community Medicine And Public Health. 2017. p. 903. Available from: http://dx.doi.org/10.18203/2394-6040.ijcmph20171305

3. Seecheran N, Nandlal N, Nankissoon S, Nanoo C, Nelson C, Nkemakolam A, et al. A trinidadian cardiovascular medication adherence survey: the ADHERE TNT study [Internet]. Vol. 4, International Journal Of Community Medicine And Public Health. 2017. p. 3601. Available from: http://dx.doi.org/10.18203/2394-6040.ijcmph20174218

4. Huffman JC, Celano CM, Beach SR, Motiwala SR, Januzzi JL. Depression and cardiac disease: epidemiology, mechanisms, and diagnosis. Cardiovasc Psychiatry Neurol [Internet]. 2013 Apr 7;2013:695925. Available from: http://dx.doi.org/10.1155/2013/695925

5. Maharaj RG. Depression and the nature of Trinidadian family practice: a cross-sectional study. BMC Fam Pract [Internet]. 2007 Apr 26;8:25. Available from: http://dx.doi.org/10.1186/1471-2296-8-25

6. Maharaj RG, Reid SD, Misir A, Simeon DT. Depression and its associated factors among patients attending chronic disease clinics in southwest Trinidad [Internet]. Vol. 54, West Indian Medical Journal. 2005. Available from: http://dx.doi.org/10.1590/s0043-31442005000600005

7. Bahall M. Prevalence and associations of depression among patients with cardiac diseases in a public health institute in Trinidad and Tobago. BMC Psychiatry [Internet]. 2019 Jan 7;19(1):4. Available from: https://doi.org/10.1186/s12888-018-1977-3

8. Changoor TMR, Hutchinson G. The prevalence of depressive symptoms in a Trinidadian cardiac population. West Indian Med J [Internet]. 2013 Sep;62(7):620–7. Available from: http://dx.doi.org/10.7727/wimj.2013.149

9. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry [Internet]. 2010 Oct;9(3):155–61. Available from:
10. Roest AM, de Jonge P. The heart of the matter: in search of causal effects of depression on somatic diseases. BMC Med [Internet]. 2018 Aug 23;16(1):147. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106936/

11. Fiedorowicz JG. Depression and cardiovascular disease: an update on how course of illness may influence risk. Curr Psychiatry Rep [Internet]. 2014 Oct;16(10):492. Available from: http://dx.doi.org/10.1007/s11920-014-0492-6

12. Januzzi JL, Stern TA, Pasternak RC, DeSanctis RW. The Influence of Anxiety and Depression on Outcomes of Patients With Coronary Artery Disease. Arch Intern Med [Internet]. 2000 Jul 10 [cited 2019 Jan 5];160(13):1913–21. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485397

13. Chaddha A, Robinson EA, Kline-Rogers E, Alexandris-Souphis T, Rubenfire M. Mental Health and Cardiovascular Disease. Am J Med [Internet]. 2016 Nov;129(11):1145–8. Available from: http://dx.doi.org/10.1016/j.amjmed.2016.05.018

14. Kronish IM, Krupka DJ, Davidson KW. How Should We Treat Depression in Patients with Cardiovascular Disease? Dialog Cardiovasc Med [Internet]. 2012;17(2):126–33. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771386/

15. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation [Internet]. 2008 Oct 21;118(17):1768–75. Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.108.190769

16. Ceccarini M, Manzoni GM, Castelnuovo G. Assessing depression in cardiac patients: what measures should be considered? Depress Res Treat [Internet]. 2014 Feb 6;2014:148256. Available from: http://dx.doi.org/10.1155/2014/148256
17. Kohrt BA, Luitel NP, Acharya P, Jordans MJD. Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal. BMC Psychiatry [Internet]. 2016 Mar 8;16:58. Available from: http://dx.doi.org/10.1186/s12888-016-0768-y

18. Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry [Internet]. 2009 Jan;6(1):38–51. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719442/

19. Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med [Internet]. 2010 Jul;8(4):348–53. Available from: http://dx.doi.org/10.1370/afm.1139

20. Carey M, Jones KA, Yoong SL, D’Este C, Boyes AW, Paul C, et al. Comparison of a single self-assessment item with the PHQ-9 for detecting depression in general practice. Fam Pract [Internet]. 2014 Aug 1;31(4):483–9. Available from: http://dx.doi.org/10.1093/fampra/cmu018

21. Sahni A, Agius M. The Use of the PHQ9 self-rating scale to assess depression within Primary Care. Psychiatr Danub [Internet]. 2017 Sep;29(Suppl 3):615–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28953840

22. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med [Internet]. 2001 Sep;16(9):606–13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11556941

23. Reynolds WM. The PHQ-9 works well as a screening but not diagnostic instrument for depressive disorder. Evid Based Ment Health [Internet]. 2010 Aug;13(3):96. Available from: http://dx.doi.org/10.1136/ebmh.13.3.96

24. Inoue T, Tanaka T, Nakagawa S, Nakato Y, Kameyama R, Boku S, et al. Utility and limitations of PHQ-9 in a clinic specializing in psychiatric care. BMC Psychiatry [Internet]. 2012 Jul 3;12:73. Available from: http://dx.doi.org/10.1186/1471-244X-12-73

25. Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med [Internet]. 2006 Jun;21(6):547–52. Available from: http://dx.doi.org/10.1111/j.1525-
26. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J [Internet]. 2014 Jun 1;35(21):1365–72. Available from: http://dx.doi.org/10.1093/eurheartj/eht462

27. Padhy SK, Sarkar S, Davuluri T, Malhotra N. Depression as a risk factor for cardiac illness – What do we know about? Journal of Indian College of Cardiology [Internet]. 2015 Jun 1;5(2):123–30. Available from: http://www.sciencedirect.com/science/article/pii/S1561881115000206

28. Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci [Internet]. 2015 Jul;40(4):219–21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26107348

29. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry [Internet]. 2017 Feb;4(2):146–58. Available from: http://dx.doi.org/10.1016/S2215-0366(16)30263-2

30. Dunlop DD, Song J, Lyons JS, Manheim LM, Chang RW. Racial/ethnic differences in rates of depression among preretirement adults. Am J Public Health [Internet]. 2003 Nov;93(11):1945–52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14600071

31. González HM, Tarraf W, Whitfield KE, Vega WA. The epidemiology of major depression and ethnicity in the United States. J Psychiatr Res [Internet]. 2010 Nov;44(15):1043–51. Available from: http://dx.doi.org/10.1016/j.jpsychires.2010.03.017

32. Ethnic minority membership and depression in the UK and America. Mental Health and Social Inclusion [Internet]. 2017 Jan 30 [cited 2019 Feb 5]; Available from: http://www.emeraldinsight.com/doi/10.1108/MHSI-12-2016-0037

33. Peyrot WJ, Lee SH, Milaneschi Y, Abdellaoui A, Byrne EM, Esko T, et al. The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25,000 subjects. Mol Psychiatry [Internet]. 2015 Jun;20(6):735–43. Available from: http://dx.doi.org/10.1038/mp.2015.50

34. Shi J, Zhang Y, Liu F, Li Y, Wang J, Flint J, et al. Associations of educational attainment, occupation, social class and major depressive disorder among Han Chinese women. PLoS One [Internet]. 2014 Jan 31;9(1):e86674. Available from: http://dx.doi.org/10.1371/journal.pone.0086674
35. Bjelland I, Krokstad S, Mykletun A, Dahl AA, Tell GS, Tambs K. Does a higher educational level protect against anxiety and depression? The HUNT study. Soc Sci Med [Internet]. 2008 Mar;66(6):1334–45. Available from: http://dx.doi.org/10.1016/j.socscimed.2007.12.019

36. Bauldry S. Variation in the Protective Effect of Higher Education Against Depression. Soc Ment Health [Internet]. 2015 Jul;5(2):145–61. Available from: http://dx.doi.org/10.1177/2156869314564399

37. Patel V, Burns JK, Dhingra M, Tarver L, Kohrt BA, Lund C. Income inequality and depression: a systematic review and meta-analysis of the association and a scoping review of mechanisms. World Psychiatry [Internet]. 2018 Feb;17(1):76–89. Available from: http://dx.doi.org/10.1002/wps.20492

38. van Deurzen I, van Ingen E, van Oorschot WJH. Income Inequality and Depression: The Role of Social Comparisons and Coping Resources. Eur Sociol Rev [Internet]. 2015 Aug 1 [cited 2019 Feb 5];31(4):477–89. Available from: https://academic.oup.com/esr/article/31/4/477/496590

39. Martikainen P, Adda J, Ferrie JE, Davey Smith G, Marmot M. Effects of income and wealth on GHQ depression and poor self rated health in white collar women and men in the Whitehall II study. J Epidemiol Community Health [Internet]. 2003 Sep;57(9):718–23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12933779

40. Santos MJ dos, Kawamura HC, Kassouf AL. Socioeconomic Conditions and Risk of Mental Depression: An Empirical Analysis for Brazilian Citizens. Economics Research International [Internet]. 2012 Apr 17 [cited 2019 Feb 5];2012. Available from: https://www.hindawi.com/journals/ecri/2012/278906/

41. Sareen J, Afifi TO, McMillan KA, Asmundson GJG. Relationship between household income and mental disorders: findings from a population-based longitudinal study. Arch Gen Psychiatry [Internet]. 2011 Apr;68(4):419–27. Available from: http://dx.doi.org/10.1001/archgenpsychiatry.2011.15

42. Rubio-Guerra AF, Rodriguez-Lopez L, Vargas-Ayala G, Huerta-Ramirez S, Serna DC, Lozano-Nuevo JJ. Depression increases the risk for uncontrolled hypertension. Exp Clin Cardiol [Internet]. 2013 Winter;18(1):10–2. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24294029

43. Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine [Internet]. 2015 Aug;94(31):e1317. Available from:
44. Frederick FT, Maharaj HD. Prevalence of depression in type 2 diabetic patients in Trinidad and Tobago. West Indian Med J [Internet]. 2013 Sep;62(7):628-31. Available from: http://dx.doi.org/10.7727/wimj.2012.329

45. Mohamed R, Abdul Kadir A, Yaacob LH. A study on depression among patient with type 2 diabetes mellitus in North-Eastcoast Malaysia. International Journal of Collaborative Research on Internal Medicine & Public Health [Internet]. 2012;4(8):1589–600. Available from: http://internalmedicine.imedpub.com/a-study-on-depression-among-patient-with-type-2-diabetesmellitus-in-northeastcoast-malaysia.php?aid=6336

46. Salinero-Fort MA, Gómez-Campelo P, San Andrés-Rebollo FJ, Cárdenas-Valladolid J, Abánades-Herranz JC, Carrillo de Santa Pau E, et al. Prevalence of depression in patients with type 2 diabetes mellitus in Spain (the DIADEMA Study) : results from the MADIABETES cohort. BMJ Open [Internet]. 2018 Sep 24;8(9):e020768. Available from: http://dx.doi.org/10.1136/bmjopen-2017-020768

47. Bai X, Liu Z, Li Z, Yan D. The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis. BMJ Open [Internet]. 2018 Nov 28;8(11):e020062. Available from: http://dx.doi.org/10.1136/bmjopen-2017-020062

48. Katon WJ, Lin EHB, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med [Internet]. 2010 Dec 30;363(27):2611–20. Available from: http://dx.doi.org/10.1056/NEJMoa1003955

49. Hörnsten C, Lövheim H, Nordström P, Gustafson Y. The prevalence of stroke and depression and factors associated with depression in elderly people with and without stroke. BMC Geriatr [Internet]. 2016 Oct 7;16(1):174. Available from: http://dx.doi.org/10.1186/s12877-016-0347-6

50. Hawamdeh S, Almari AM, Almutairi AS, Dator WLT. Determinants and prevalence of depression in patients with chronic renal disease, and their caregivers. Int J Nephrol Renovasc Dis [Internet]. 2017 Jul 3;10:183–9. Available from: http://dx.doi.org/10.2147/IJN RD.S139652

51. Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and
Management. Kidney Int Rep [Internet]. 2017 Jan;2(1):94-107. Available from:
http://dx.doi.org/10.1016/j.ekir.2016.09.005

52. Stage KB, Middelboe T, Stage TB, Sørensen CH. Depression in COPD--management and quality of life considerations. Int J Chron Obstruct Pulmon Dis [Internet]. 2006;1(3):315-20. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/18046868

53. Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev [Internet]. 2014 Sep;23(133):345-9. Available from: http://dx.doi.org/10.1183/09059180.00007813

54. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA [Internet]. 2002 Jul 17;288(3):351-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12117400

55. Stanton AV. Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. BMJ [Internet]. 1998 May 16;316(7143):1471-3. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/9582126

56. Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry [Internet]. 2014 Dec 4;14:348. Available from:
http://dx.doi.org/10.1186/s12888-014-0348-y

57. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med [Internet]. 2009 Sep 10;361(11):1045-57. Available from: http://dx.doi.org/10.1056/NEJMoa0904327

58. Ticagrelor (Brilinta) and a possible association with depression / suicidality added to the Medicines Monitoring Scheme [Internet]. [cited 2019 Mar 2]. Available from:
https://medsafe.govt.nz/safety/EWS/2016/Ticagrelor.asp#Ticagrelor

59. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol [Internet]. 2007 Jul 3;7:30. Available from:
http://dx.doi.org/10.1186/1471-2288-7-30

https://www.who.int/mental_health/management/depression/en/

Tables
### Table 1
Demographics of study participants.

| Demographics (n = 1203) | Percentage |
|-------------------------|------------|
| Age* (years)            | 62.5 ± 13.1 (Range) |
| Gender+                 |            |
| Male                    | 571 (47.5%) |
| Female                  | 632 (52.5%) |
| Education+              |            |
| None                    | 9 (6.6%)   |
| Primary                 | 595 (49.5%) |
| Secondary               | 400 (33.3%) |
| Tertiary                | 129 (10.7%) |
| Income+                 |            |
| None                    | 339 (28.2%) |
| Pensioner               | 631 (52.5%) |
| $5000 - $10,000 TTD     | 196 (16.3%) |
| > $10,000 TTD           | 37 (3.1%)  |
| Ethnicity+              |            |
| South Asian             | 690 (57.4%) |
| Caribbean Black         | 379 (1.5%)  |
| Interracial and/or other| 134 (1.1%)  |

### Table 2
Comorbidities.

| Comorbidity (n = 1203) | Percentage |
|------------------------|------------|
| Cardiovascular disease (CVD) (definite) | 1085 (90.2%) |
| Diabetes Mellitus (DM) | 576 (47.95%) |
| Hypertension (HTN)     | 860 (71.5%) |
| Dyslipidemia (HLD)     | 614 (51.0%) |
| Cerebrovascular Events (CVE) | 139 (11.6%) |
| Chronic Kidney Disease (CKD) | 101 (8.4%) |
| Chronic Obstructive Pulmonary Disease (COPD) | 69 (5.7%) |
| Peripheral Vascular Disease (PVD) | 115 (9.6%) |

### Table 3
Cardiovascular Medications.

| Cardiovascular Medication (n = 1203) | Percentage |
|--------------------------------------|------------|
| Aspirin                              | 826 (68.7%) |
| Clopidogrel                           | 382 (31.8%) |
| Ticagrelor                            | 27 (2.2%)   |
| Vitamin K antagonists (VKA)          | 112 (9.3%)  |
| Direct Oral Anticoagulants (DOAC)    | 14 (1.2%)   |
|Angiotensin-Converting Enzyme inhibitors (ACEi) | 505 (42.0%) |
| Angiotensin Receptor Blockers (ARB)   | 150 (12.5%) |
| Beta Blockers (BB)                    | 538 (44.7%) |
| Statin                               | 644 (53.5%) |
| Mineralocorticoid Receptor Antagonist (MRA) | 61 (5.1%)  |
| Loop diuretics                       | 211 (17.5%) |
| Ivabradine                            | 88 (7.3%)   |
| Calcium Channel Blockers (CCB)       | 204 (17.0%) |
| Nitrates                             | 282 (23.4%) |
| Trimetazidine                         | 313 (26.0%) |
| Analgesics                            | 23 (1.9%)   |
Table 4
Association between demographics and significant depressive symptoms (PHQ-9 ≥ 10).

| Demographic          | PHQ-9 < 10 (n = 899) | PHQ-9 ≥ 10 (n = 304) | p-value |
|----------------------|-----------------------|-----------------------|---------|
| *Age (years) mean ± SD | 62.57 ± 13.1          | 60.88 ± 13.1          | 0.052   |
| Gender + Male        | 463 (51.5%)           | 108 (35.5%)           | < 0.001 |
|                      | 436 (48.5%)           | 196 (64.5%)           |         |
| Education + None     | 46 (5.1%)             | 33 (10.9%)            | 0.001   |
|                      | 432 (48.1%)           | 163 (53.6%)           |         |
|                      | 317 (35.3%)           | 83 (27.3%)            |         |
|                      | 104 (11.6%)           | 25 (8.2%)             |         |
| Income + None        | 221 (24.6%)           | 118 (38.8%)           | < 0.001 |
|                      | 490 (54.5%)           | 141 (46.4%)           |         |
|                      | 154 (17.1%)           | 42 (13.8%)            |         |
|                      | 34 (3.8%)             | 3 (1.0%)              |         |
| Ethnicity ~ South Asian | 510 (56.7%)         | 180 (59.2%)           | 0.426   |
|                      | 292 (32.5%)           | 87 (28.6%)            |         |
|                      | 97 (10.8%)            | 37 (12.2%)            |         |

*Independent Sample t-test
+Fisher's Exact test
~Chi-Square test

Table 5
Association between comorbidities significant depressive symptoms (PHQ-9 ≥ 10).

| Comorbidity                                | Unadjusted Odds Ratio (95% CI) | Adjusted Odds Ratio* (95% CI) |
|--------------------------------------------|--------------------------------|--------------------------------|
| Hypertension (HTN)                         | 1.821 (1.330–2.492)            | 1.988 (1.414–2.797)           |
| Dyslipidemia (HLD)                         | 1.347 (1.037–1.750)            | 1.263 (0.965–1.653)           |
| Cerebrovascular Events (CVE)               | 1.665 (1.142–2.427)            | 1.847 (1.251–2.728)           |
| Chronic Kidney Disease (CKD)               | 1.896 (1.239–2.901)            | 1.872 (1.207–2.902)           |
| Chronic Obstructive Pulmonary Disease (COPD)| 1.741 (1.046–2.897)            | 1.703 (1.009–2.876)           |

*Adjusted for Age, Gender, Education, and Income.

Table 6
Association between cardiovascular medication use and significant depressive symptoms (PHQ-9 ≥ 10).

| Drug                                       | *PHQ-9 < 10 (n = 899) | *PHQ-9 ≥ 10 (n = 304) | p-value |
|--------------------------------------------|-----------------------|-----------------------|---------|
| Aspirin                                    | 606 (67.4%)           | 220 (72.4%)           | 0.116   |
| Clopidogrel                                 | 291 (32.4%)           | 91 (29.9%)            | 0.476   |
| Ticagrelor                                  | 12 (1.3%)             | 15 (4.9%)             | 0.001   |
| Vitamin K antagonists (VKA)                | 81 (9.0%)             | 31 (10.2%)            | 0.568   |
| Direct Oral Anticoagulants (DOAC)          | 11 (1.2%)             | 3 (1.0%)              | > 0.99  |
| Angiotensin Converting Enzyme inhibitor (ACEi)| 363 (40.4%)         | 142 (46.7%)           | 0.060   |
| Angiotensin Receptor Blocker (ARB)         | 113 (12.6%)           | 37 (12.2%)            | 0.920   |
| Beta Blocker (BB)                          | 399 (44.4%)           | 139 (45.7%)           | 0.689   |
| Statin                                     | 473 (52.6%)           | 171 (56.2%)           | 0.287   |
| Mineralocorticoid Receptor Antagonist (MRA)| 41 (4.6%)             | 20 (6.6%)             | 0.174   |
| Loop diuretic                              | 151 (16.8%)           | 60 (19.7%)            | 0.257   |
| Ivabradine                                  | 71 (7.9%)             | 17 (5.6%)             | 0.204   |
| Calcium Channel Blocker (CCB)              | 149 (16.6%)           | 55 (18.1%)            | 0.537   |
| Nitrates                                   | 202 (22.5%)           | 80 (26.3%)            | 0.183   |
| Trimetazidine                               | 222 (24.7%)           | 91 (29.9%)            | 0.082   |
| Analgesics                                  | 14 (1.6%)             | 9 (3.0%)              | 0.145   |

*Frequency (percentages)